CN113101303B - 自发性凋亡的间充质干细胞的制备方法及用途 - Google Patents
自发性凋亡的间充质干细胞的制备方法及用途 Download PDFInfo
- Publication number
- CN113101303B CN113101303B CN202110406571.5A CN202110406571A CN113101303B CN 113101303 B CN113101303 B CN 113101303B CN 202110406571 A CN202110406571 A CN 202110406571A CN 113101303 B CN113101303 B CN 113101303B
- Authority
- CN
- China
- Prior art keywords
- mscs
- mesenchymal stem
- stem cells
- dmscs
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 141
- 230000001640 apoptogenic effect Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 230000002269 spontaneous effect Effects 0.000 title claims abstract description 10
- 230000006907 apoptotic process Effects 0.000 claims abstract description 20
- 208000004852 Lung Injury Diseases 0.000 claims abstract description 14
- 206010069363 Traumatic lung injury Diseases 0.000 claims abstract description 14
- 231100000515 lung injury Toxicity 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 206010067125 Liver injury Diseases 0.000 claims abstract description 12
- 208000020431 spinal cord injury Diseases 0.000 claims abstract description 10
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 8
- 230000000451 tissue damage Effects 0.000 claims abstract description 8
- 231100000827 tissue damage Toxicity 0.000 claims abstract description 8
- 239000007924 injection Substances 0.000 claims description 39
- 238000002347 injection Methods 0.000 claims description 39
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000003116 impacting effect Effects 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 59
- 241000699670 Mus sp. Species 0.000 abstract description 53
- 238000000034 method Methods 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 11
- 239000001963 growth medium Substances 0.000 abstract description 10
- 230000008439 repair process Effects 0.000 abstract description 6
- 238000012258 culturing Methods 0.000 abstract description 5
- 230000017423 tissue regeneration Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 208000037816 tissue injury Diseases 0.000 abstract description 2
- 238000011269 treatment regimen Methods 0.000 abstract description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 abstract 2
- 239000008055 phosphate buffer solution Substances 0.000 description 49
- 210000003462 vein Anatomy 0.000 description 28
- 210000004185 liver Anatomy 0.000 description 17
- CJYQQUPRURWLOW-YDLUHMIOSA-M dmsc Chemical compound [Na+].OP(=O)=O.OP(=O)=O.OP(=O)=O.[O-]P(=O)=O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O CJYQQUPRURWLOW-YDLUHMIOSA-M 0.000 description 15
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 102000003952 Caspase 3 Human genes 0.000 description 9
- 108090000397 Caspase 3 Proteins 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 9
- 210000005228 liver tissue Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 210000003437 trachea Anatomy 0.000 description 9
- 230000001575 pathological effect Effects 0.000 description 8
- 230000002685 pulmonary effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000002303 tibia Anatomy 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102000004225 Cathepsin B Human genes 0.000 description 4
- 108090000712 Cathepsin B Proteins 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 102100025304 Integrin beta-1 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- -1 CD86 Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000005206 flow analysis Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000021058 soft food Nutrition 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110406571.5A CN113101303B (zh) | 2021-04-15 | 2021-04-15 | 自发性凋亡的间充质干细胞的制备方法及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110406571.5A CN113101303B (zh) | 2021-04-15 | 2021-04-15 | 自发性凋亡的间充质干细胞的制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113101303A CN113101303A (zh) | 2021-07-13 |
CN113101303B true CN113101303B (zh) | 2023-04-07 |
Family
ID=76717774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110406571.5A Active CN113101303B (zh) | 2021-04-15 | 2021-04-15 | 自发性凋亡的间充质干细胞的制备方法及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113101303B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115054568A (zh) * | 2022-04-14 | 2022-09-16 | 赣南医学院第一附属医院 | 促进脊髓损伤恢复的温敏型水凝胶及制备方法 |
CN116036087B (zh) * | 2022-12-26 | 2023-09-05 | 中国人民解放军空军军医大学 | 铁死亡抑制剂在制备修复受损肝脏药物中的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017160986A1 (en) * | 2016-03-16 | 2017-09-21 | Cell Medicine, Inc. | Mesenchymal stem cells with enhanced efficacy |
WO2017179767A1 (ko) * | 2016-04-12 | 2017-10-19 | 서울대학교 산학협력단 | 지방줄기세포에서 신경줄기세포, 신경세포 및 가바성 신경세포로의 분화 유도 방법, 및 인간 골수 유래 중간엽 줄기세포로부터 성장인자를 다량 분비하는 인간 줄기세포의 분화 유도 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009146746A1 (en) * | 2008-06-05 | 2009-12-10 | Universite Libre De Bruxelles | Use of fxa, fviia, tf, or a combination thereof as anti-apoptotic agents |
WO2013186264A1 (en) * | 2012-06-12 | 2013-12-19 | Universitätsspital Basel | Immortalized mesenchymal stem cells that can be killed through an inducible apoptosis system |
EP3177303B1 (en) * | 2014-08-08 | 2020-07-29 | Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California | Apoptotic bodies |
CN105238746A (zh) * | 2015-09-21 | 2016-01-13 | 深圳华毓造血干细胞研究有限公司 | 骨髓间充质干细胞的诱导方法及其诱导液 |
CN113768953B (zh) * | 2021-09-02 | 2023-10-13 | 中国人民解放军空军军医大学 | 凋亡小体用于制备治疗急性肺损伤药物的应用 |
-
2021
- 2021-04-15 CN CN202110406571.5A patent/CN113101303B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017160986A1 (en) * | 2016-03-16 | 2017-09-21 | Cell Medicine, Inc. | Mesenchymal stem cells with enhanced efficacy |
WO2017179767A1 (ko) * | 2016-04-12 | 2017-10-19 | 서울대학교 산학협력단 | 지방줄기세포에서 신경줄기세포, 신경세포 및 가바성 신경세포로의 분화 유도 방법, 및 인간 골수 유래 중간엽 줄기세포로부터 성장인자를 다량 분비하는 인간 줄기세포의 분화 유도 방법 |
Also Published As
Publication number | Publication date |
---|---|
CN113101303A (zh) | 2021-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106109496B (zh) | 人脐带间充质干细胞提取物冻干粉及制备方法 | |
Gendler et al. | Toxic reactions evoked by glutaraldehyde‐fixed pericardium and cardiac valve tissue bioprosthesis | |
JP5240715B2 (ja) | 脂肪組織由来多分化能幹細胞を含有する細胞製剤 | |
CN113101303B (zh) | 自发性凋亡的间充质干细胞的制备方法及用途 | |
CN108685948B (zh) | 一种医用细胞修复剂的制备方法 | |
JPWO2003043651A1 (ja) | 多分化能幹細胞を組織から末梢血へ動員する薬剤 | |
CN103585177A (zh) | 间充质干细胞和基因修饰的间充质干细胞的用途 | |
CN111471650B (zh) | 一种人脐带间充质干细胞来源的外泌体、鉴定方法及应用 | |
CN105534848A (zh) | 一种化妆品或药物组合物及其用途 | |
KR20180008526A (ko) | 중간엽 줄기 세포를 포함하는 조성물 및 그의 용도 | |
CN109893541B (zh) | 经血干细胞来源的外泌体在制备治疗宫腔粘连的药物中的应用 | |
Aygit et al. | The fate of intramuscularly injected fat autografts: an experimental study in rabbits | |
JP2020172536A (ja) | 創傷治癒のための幹細胞 | |
CN108642002A (zh) | 一种无血清驯化培养人间充质干细胞的方法 | |
JPWO2004101775A1 (ja) | 新規な成体組織由来の幹細胞およびその用途 | |
Ding et al. | Galectin-1-induced skeletal muscle cell differentiation of mesenchymal stem cells seeded on an acellular dermal matrix improves injured anal sphincter | |
US20200288700A1 (en) | Stem cell preparations and application in the preparation of drugs for the treatment of osteoarthritis | |
CN107349220A (zh) | 一种包含成纤维细胞外泌体的制剂及其用途 | |
CN109689074A (zh) | 采用多能干细胞的缺血再灌注肺损伤的减轻及治疗 | |
CN108066750A (zh) | 干细胞及其分泌物用于治疗皮肤烧烫伤的新用途 | |
KR101834800B1 (ko) | 심장 조직-유래 세포 | |
WO2020181753A1 (zh) | 干细胞制剂及其在制备治疗骨关节炎的药物中的应用 | |
CN108066824A (zh) | 一种制备表皮缺损治疗药物的新方法 | |
WO2004045666A1 (ja) | 臓器の再生方法 | |
CN110772534A (zh) | 多系分化持续应激细胞在制备抗炎药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240419 Address after: No. 57-931 Qunyi Road, Damian Street, Longquanyi District, Chengdu City, Sichuan Province, 610000 Patentee after: Chengdu Xinghuo Jiuchen Biotechnology Partnership Enterprise (Limited Partnership) Country or region after: China Address before: 610065, No. 24, south section of first ring road, Chengdu, Sichuan, Wuhou District Patentee before: SICHUAN University Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240429 Address after: Building A9, Automotive Intelligent Innovation Vitality Port, No. 1666 South 1st Road, Chengdu Economic and Technological Development Zone (Longquanyi District), Chengdu City, Sichuan Province, 610000 Patentee after: Chengdu Yinmunuo Biopharmaceutical Co.,Ltd. Country or region after: China Address before: No. 57-931 Qunyi Road, Damian Street, Longquanyi District, Chengdu City, Sichuan Province, 610000 Patentee before: Chengdu Xinghuo Jiuchen Biotechnology Partnership Enterprise (Limited Partnership) Country or region before: China |
|
TR01 | Transfer of patent right |